Base de dados : HANSEN
Pesquisa : CLOFAZIMINA/FARMACOL [Descritor de assunto]
Referências encontradas : 11 [refinar]
Mostrando: 1 .. 11   no formato [Detalhado]

página 1 de 1

  1 / 11 HANSEN  
              next record last record
seleciona
para imprimir
Id:25129
Autor:Leonard Wood Memorial*.
Título:A statistical analysis of two chemotherapy trials in lepromatous leprosy: II. Interactions among patient variables
..-
Fonte:s.l; s.n; 1978. 4 p. tab.
Resumo:Interrelationship among six patient characteristics recorded upon entry the trial were analyzed for 67 patients with lepromatous and near-lepromatous leproay admitted into two chemotherapy trials. Sex was found to be significantly associated with age and with the histopathologic classification; disproportionately large numbers of older patients and of patients classified as borderline-lepromatous (BL) were males. Classifications of the disease process by clinical and histopathologic criteria were closely associated, but many patients classified BL on histopathological grounds were classified fully lepromatous by the clinical criteria. Measurments of the number of Mycobacterium leprae in the patients made by there methods were also significantly correlated. No significant correlations were found between either classification of the disease process on the hand, and any of the measurments of the numbers of organisms on the other (AU).
Descritores:HANSENIASE DIMORFA/terap
HANSENIASE VIRCHOWIANA/terap
CLOFAZIMINA/admin
CLOFAZIMINA/farmacol
CLOFAZIMINA/uso terap
RIFAMPINA/uso terap
DAPSONA/uso terap
HANSENIASE DIMORFA/microbiol
HANSENIASE DIMORFA/patol
HANSENIASE VIRCHOWIANA/microbiol
HANSENIASE VIRCHOWIANA/patol
QUIMIOTERAPIA COMBINADA
 DROGAS EM INVESTIGACAO/admin
 DROGAS EM INVESTIGACAO/uso terap
Limites:ESTUDO COMPARATIVO
HUMANO
Localização:BR191.1; 00294/s


  2 / 11 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:24713
Autor:Sampaio, Sebastiao AP; Rivitti, Evandro A.
Título:Hanseníase / Leprosy
Fonte:In: Sampaio, Sebastiao AP; Rivitti, Evandro A.Dermatologia. Sao Paulo, Artes Medicas, 2007. p.625-651ilus, graf.
Descritores:HANSENIASE/imunol
HANSENIASE/microbiol
HANSENIASE/prev
HANSENIASE/fisiopatol
HANSENIASE/reabil
HANSENIASE/terap
MYCOBACTERIUM LEPRAE/citol
MYCOBACTERIUM LEPRAE/genet
MYCOBACTERIUM LEPRAE/imunol
MYCOBACTERIUM LEPRAE/fisiol
ANTIGENO DE MITSUDA/quim
ANTIGENO DE MITSUDA/fisiol
RIFAMPINA/farmacol
 RIFAMPINA/uso terap
 DAPSONA/farmacol
 DAPSONA/uso terap
 CLOFAZIMINA/farmacol
 CLOFAZIMINA/uso terap
Limites:ESTUDO COMPARATIVO
HUMANO
Localização:Br191.1; WR100, S47d


  3 / 11 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:20767
Autor:Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat
Título:Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages
..-
Fonte:s.l; s.n; 2003. 10 p. graf.
Resumo:Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU).
Descritores:ANTIINFECCIOSOS/quim
ANTIINFECCIOSOS/farmacol
ANTIINFECCIOSOS/tox
CELULAS CULTIVADAS
CLOFAZIMINA/quim
CLOFAZIMINA/farmacol
CLOFAZIMINA/tox
MACROFAGOS/ef drogas
TESTES DE SENSIBILIDADE MICROBIANA
COMPLEXO MYCOBACTERIUM AVIUM/ef drogas
ESTEROIS/quim
ACIDO SUCCINICO
Limites:ESTUDO COMPARATIVO
HUMANO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 09082/s


  4 / 11 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18954
Autor:Salem, Isam Ismail; Steffan, Gerhard; Düzgünes, Nejat
Título:Efficacy of clofazimine - modified cyclodextrin against Mycobacterium avium complex in human macrophages
..-
Fonte:s.l; s.n; 2003. 10 p. graf.
Resumo:Clofazimine, a water insoluble substituted iminophenazine derivative with anti-mycobacterial and anti-inflammatory activity, is recommended by the WHO for the treatment of leprosy. It is also active against disseminated Mycobacterium avium complex (MAC) disease in HIV-infected patients. Recently, we achieved a 4000-fold increase of clofazimine water solubility using a novel modified clofazimine-cyclodextrin complex synthesized and patented by our group [Wasserlösliche, Iminiophenazinderivate enthaltende pharmazeutische Zusammensetzungen, deren Herstellung und Verwendung, German Patent, DE19814814C2]. In this paper we examine the activity of this complex against MAC in human macrophages, and evaluate its cytotoxicity. MAC-infected macrophages were treated for 24h with free or complexed clofazimine. The in vitro minimum inhibitory concentrations of both free and complexed clofazimine were 0.1 microg/ml. Free and complexed clofazimine inhibited the growth of MAC inside macrophages to a similar extent, while modified cyclodextrin alone had no observable effects on MAC or macrophages. Complexed clofazimine was not toxic to cells at concentrations effective against MAC. The TD(50) of the modified cyclodextrin in THP-1 cell line was 297 microg/ml. (AU).
Descritores:ANTIINFECCIOSOS/quim
ANTIINFECCIOSOS/farmacol
ANTIINFECCIOSOS/tox
CLOFAZIMINA/quim
CLOFAZIMINA/farmacol
CLOFAZIMINA/tox
CELULAS CULTIVADAS
MACROFAGOS/ef drogas
MACROFAGOS/microbiol
TESTES DE SENSIBILIDADE MICROBIANA
COMPLEXO MYCOBACTERIUM AVIUM/ef drogas
ESTEROIS/quim
ACIDO SUCCINICO/quim
Limites:ESTUDO COMPARATIVO
HUMANO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 09082/s


  5 / 11 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18038
Autor:Holmes, I. B; Banerjee, D. K; Hilson, G. R
Título:Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection
..-
Fonte:s.l; s.n; apr. 1976. 5 p. graf.
Resumo:Continuous dietary administration of rifampin to mice with an established Mycobacterium leprae footpad infection reduced the bacillary solid ratio, with an estimated survival half-life of 5-6 days. In rifampin-treated immunosuppressed animals the survival half-life of solid bacilli, in the absence of host immunity, was 12-13 days. Clofazimine and B1912 produced a significant effect on solid ratio only after a lag period of apparently 100 days. The rate of action was considerably slower than that of rifampin. Intermittent (once monthly) administration of both drugs produced effects similar to those of continuous administration.(AU).
Descritores:ANTICORPOS ANTIBACTERIAS
CLOFAZIMINA/analog
CLOFAZIMINA/farmacol
CLOFAZIMINA/uso terap
IMUNOSSUPRESSAO
HANSENIASE/quimioter
HANSENIASE/imunol
MYCOBACTERIUM LEPRAE/ef drogas
MYCOBACTERIUM LEPRAE/imunol
FATORES DE TEMPO
RIFAMPINA/farmacol
RIFAMPINA/uso terap
Limites:ESTUDO COMPARATIVO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 01652/s


  6 / 11 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17968
Autor:Dubey, G. K; Joglekar, V. K; Hardas, U. D; Chaubey, B. S
Título:A study of cell mediated immunity in leprosy
..-
Fonte:s.l; s.n; apr. 1981. 7 p. tab, graf.
Resumo:This paper presents a review of 123 cases of leprosy of different clinical types as regards to their status of cellular immunity. These 123 cases included 41 fresh cases, 18 cases of reaction and 64 cases of leprosy taking antileprosy treatment. Out of 41 untreated cases only 11 turned up for follow up and their lymphoblastic transformation was repeated 4 to 6 months after initiating the treatment. It was observed that cell mediated immunity as expressed in terms of percentage of blast cells is definitely depressed in leprosy, most in LL and least in TT. There is a definite increase in the percentage of blast cells after taking antileprosy treatment. The rise in percentage of blast cells and hence cellular immunity is relatively more in patients treated with Lamprene as compared to those treated with DDS. Reactions also have impact over immunity in leprosy. Thus, most of the patients with ENL show higher values for blast percentage as compared to those with lepra reaction. It appears that serial lymphocyte cultures if done in all cases of leprosy undergoing treatment will help in assessment of individual progress.(AU).
Descritores:IMUNIDADE CELULAR/ef drogas
HANSENOSTATICOS/farmacol
HANSENOSTATICOS/uso terap
HANSENIASE/quimioter
HANSENIASE/imunol
CLOFAZIMINA/farmacol
CLOFAZIMINA/uso terap
DAPSONA/farmacol
DAPSONA/uso terap
Limites:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 00771/s


  7 / 11 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17835
Autor:Pieters, F. A; Woonink, F; Zuidema, J
Título:Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria
..-
Fonte:s.l; s.n; 1988. 4 p. tab, graf.
Resumo:In leprosy patients in Nigeria the influence of daily clofazimine and of once-monthly rifampicin on the pharmacokinetics of dapsone has been investigated. Three days after rifampicin the elimination half-life of dapsone was reduced from 40.4 to 25.3 h (n = 23). Correspondingly, the plasma dapsone 24 h after the last dose had fallen significantly from 2.63 to 2.02 mg/l. Clofazimine did not cause change in the pharmacokinetics of dapsone. It was concluded that, although rifampicin had a considerable influence on the pharmacokinetics of dapsone, there is no reason to adjust the dose of dapsone during multidrug therapy of leprosy.(AU).
Descritores:CLOFAZIMINA/admin
CLOFAZIMINA/farmacol
HANSENIASE/sangue
HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/farmacol
DAPSONA/admin
DAPSONA/sangue
DAPSONA/farmacocin
DAPSONA/uso terap
Limites:HUMANO
MASCULINO
FEMININO
ADULTO
MEIA-IDADE
IDOSO
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 02067/s


  8 / 11 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:14199
Autor:O'Connor, Robert; O'Sullivan, J. F; O'Kennedy, Richard
Título:The pharmacology, metabolism, and chemistry of clofazimine
..-
Fonte:s.l; s.n; 1995. 24 p. ilus, tab.
Descritores:HANSENIASE
MICOBACTERIOSE
ABSORÇAO
DISPONIBILIDADE BIOLOGICA
CROMATOGRAFIA LIQUIDA DE ALTA PRESSAO
CLOFAZIMINA
CLOFAZIMINA
CLOFAZIMINA
CLOFAZIMINA
SISTEMA IMUNE
RELAÇAO ESTRUTURA-ATIVIDADE
Localização:BR191.1; 06974/s


  9 / 11 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:13961
Autor:Mendis, Susirith; Somasiri, K. G; Chularatna, W
Título:Effect of drug treatment on electroneurological measures of peripheral nerve function in leprosy patients
..-
Fonte:s.l; s.n; 1993. 4 p. tab.
Descritores:CLOFAZIMINA
CLOFAZIMINA
DAPSONA
DAPSONA
QUIMIOTERAPIA COMBINADA
ELETROFISIOLOGIA
HANSENIASE
HANSENIASE
HANSENIASE DIMORFA
HANSENIASE DIMORFA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
CONDUÇAO NERVOSA
NERVOS PERIFÉRICOS
NERVOS PERIFÉRICOS
TEMPO DE REAÇAO
RIFAMPINA
RIFAMPINA
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
Localização:BR191.1; 06607/s


  10 / 11 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:13172
Autor:Mendes, Abraao Garcia; Campos, Wesley Ribeiro; Orefice, Fernando; Monteiro, Lilian Grace; Sucena, Maria Aparecida
Título:Impregnacao sui generis conjuntivo escleral por clofazimina em um paciente portador de hanseniase
Impregnation sui generis of the conjunctiva and sclera by clofazimine in a carrier Hansen's disease-
Fonte:s.l; s.n; 1994. 8 p. ilus.
Descritores:CONJUNTIVA
ESCLERA
HANSENIASE
CLOFAZIMINA
CLOFAZIMINA
Localização:BR191.1; 06173/s


  11 / 11 HANSEN  
              first record previous record
seleciona
para imprimir
Id:8773
Autor:Banerjee, D. K; Ellard, G. A; Gammon, Patricia T; Waters, M. F. R
Título:Some observations on the pharmacology of clofazimine (B663)
..-
Fonte:s.l; s.n; 1974. 5 p. .
Descritores:HANSENIASE
HANSENIASE
CLOFAZIMINA
 CLOFAZIMINA
 CLOFAZIMINA
Localização:BR191.1; 03831/s



página 1 de 1
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information